Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group

dc.creatorMaiztegui, Julio I.
dc.creatorMcKee Jr, Kelly T.
dc.creatorBarrera Oro, Julio G.
dc.creatorHarrison, Lee H
dc.creatorGibbs, P H
dc.creatorFeuillade, María Rosa
dc.creatorEnria, Delia
dc.creatorBriggiler, Ana M.
dc.creatorLevis, Silvana
dc.creatorAmbrosio, Ana María
dc.creatorHalsey, Neal A.
dc.creatorPeters, Clarence J.
dc.date2021-01-21T18:30:15Z
dc.date2021-01-21T18:30:15Z
dc.date1998-02
dc.date.accessioned2023-08-29T20:09:03Z
dc.date.available2023-08-29T20:09:03Z
dc.identifier0022-1899
dc.identifierhttp://sgc.anlis.gob.ar/handle/123456789/2221
dc.identifier10.1086/514211
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8520483
dc.descriptionFil: Maiztegui, Julio I. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
dc.descriptionFil: McKee Jr, K. T. Womack Army Medical Center, Fort Bragg, North Carolina; Estados Unidos.
dc.descriptionFil: Barrera Oro, J G. ANLIS Dr.C.G.Malbrán; Argentina.
dc.descriptionFil: Harrison, L H. University of Pittsburgh Graduate School of Public Health,Pittsburgh, Pennsylvania; Estados Unidos.
dc.descriptionFil: Gibbs, P H. Division of Disease Assessment, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21701; Estados Unidos.
dc.descriptionFil: Feuillade, María Rosa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
dc.descriptionFil: Enria, Delia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
dc.descriptionFil: Briggiler, Ana M. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
dc.descriptionFil: Levis, Silvana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
dc.descriptionFil: Ambrosio, Ana María. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina.
dc.descriptionFil: Halsey, N A. Department of International Health, Johns Hopkins Medical Institutions, Baltimore, Maryland; Estados Unidos.
dc.descriptionFil: Peters, C J. Special Pathogens Branch, Centers for Disease Control, Atlanta, Georgia; Estados Unidos.
dc.descriptionArgentine hemorrhagic fever (AHF), caused by the arenavirus Junin, is a major public health problem among agricultural workers in Argentina. A prospective, randomized, double-blind, placebo-controlled, efficacy trial of Candid 1, a live attenuated Junin virus vaccine, was conducted over two consecutive epidemic seasons among 6500 male agricultural workers in the AHF-endemic region. Twenty-three men developed laboratory-confirmed AHF during the study; 22 received placebo and 1 received vaccine (vaccine efficacy 95%; 95% confidence interval [CI], 82%-99%). Three additional subjects in each group developed laboratory-confirmed Junin virus infection associated with mild illnesses that did not fulfill the clinical case definition for AHF, yielding a protective efficacy for prevention of any illness associated with Junin virus infection of 84% (95% CI, 60%-94%). No serious adverse events were attributed to vaccination. Candid 1, the first vaccine for the prevention of illness caused by an arenavirus, is safe and highly efficacious.
dc.formatpdf
dc.languageen
dc.publisherOxford University Press
dc.relationThe Journal of infectious diseases
dc.rightsopen
dc.sourceJournal of infectious diseases 1998; 177(2):277-83.
dc.subjectFiebre Hemorrágica Americana
dc.subjectArenavirus
dc.subjectVirus Junin
dc.titleProtective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group
dc.typeArtículo


Este ítem pertenece a la siguiente institución